MOTS-c vs Tesofensine
A side-by-side research comparison of MOTS-c and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MOTS-c | Tesofensine |
|---|---|---|
| Full name | Mitochondrial Open Reading Frame of the 12S rRNA-c | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Activates AMPK pathway, enhances mitochondrial metabolism, improves insulin sensitivity by increasing GLUT4 translocation, and promotes fatty acid oxidation. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 2,175 Da | 329.4 Da |
| Half-life | 4-8 hours | 8-10 days |
| Bioavailability | Moderate (SubQ) | High (oral ~93%) |
| Typical dose | 5-10 mg | 0.25-0.5 mg |
| Frequency | 3-5x per week | Once daily |
| Route | Subcutaneous injection | Oral |
MOTS-c reported benefits
- Exercise mimetic effects
- Improved insulin sensitivity
- Enhanced fat oxidation
- Metabolic homeostasis
- Anti-aging metabolic benefits
- AMPK activation
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.